• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Analyst initiated coverage on Septerna with a new price target

    11/19/24 7:39:27 AM ET
    $SEPN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $SEPN alert in real time by email
    Analyst initiated coverage of Septerna with a rating of Overweight and set a new price target of $38.00
    Get the next $SEPN alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SEPN

    DatePrice TargetRatingAnalyst
    6/23/2025$26.00Buy
    H.C. Wainwright
    2/18/2025$14.00Overweight → Equal Weight
    Wells Fargo
    11/19/2024$38.00Overweight
    Analyst
    11/19/2024Buy
    TD Cowen
    11/19/2024$43.00Overweight
    Wells Fargo
    11/19/2024$50.00Overweight
    Cantor Fitzgerald
    More analyst ratings

    $SEPN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Septerna to Participate in Upcoming Investor Conferences

    SOUTH SAN FRANCISCO, Calif., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Septerna, Inc. (NASDAQ:SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today announced that management will participate in the following upcoming investor conferences in September: Cantor Global Healthcare Conference 2025 Presentation on Wednesday, September 3, 2025, at 11:30 a.m. ET 2025 Wells Fargo Healthcare ConferenceFireside chat on Friday, September 5, 2025, at 8:45 a.m. ET Live webcasts of the presentations will be available in the investors section of the company's website at www.septerna.com. Replays will be archived for at least 30 days f

    8/27/25 8:00:00 AM ET
    $SEPN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Septerna Announces Dosing of the First Participants in Phase 1 Clinical Trial of SEP-631, an Oral Small Molecule MRGPRX2 Negative Allosteric Modulator for the Treatment of Mast Cell-Driven Diseases

    SOUTH SAN FRANCISCO, Calif., Aug. 21, 2025 (GLOBE NEWSWIRE) -- Septerna, Inc. (NASDAQ:SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today announced the dosing of the first participants in its Phase 1 clinical trial of SEP-631, a selective oral small molecule Mas-related G protein-coupled receptor X2 (MRGPRX2) negative allosteric modulator (NAM) being developed for the treatment of chronic spontaneous urticaria (CSU) and other mast cell-driven diseases. The Phase 1 single-ascending dose (SAD) and multiple-ascending dose (MAD) clinical trial will evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodyna

    8/21/25 8:00:00 AM ET
    $SEPN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Septerna Highlights Business Progress and Reports Second Quarter 2025 Financial Results

    Advancing Selection of Next-Generation Oral Small Molecule PTH1R Agonist for Clinical Development Initiating Phase 1 Trial for SEP-631, MRGPRX2 NAM Program, for Mast Cell Diseases Updated Cash Runway Expected to Support Operating Plans at Least into 2029 SOUTH SAN FRANCISCO, Calif., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Septerna, Inc. (NASDAQ:SEPN), a biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today highlighted key business updates and upcoming milestones and reported financial results for the second quarter ended June 30, 2025.   "We are executing effectively across our portfolio, with each program nearing important milestones," said Je

    8/11/25 4:01:00 PM ET
    $SEPN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SEPN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    H.C. Wainwright initiated coverage on Septerna with a new price target

    H.C. Wainwright initiated coverage of Septerna with a rating of Buy and set a new price target of $26.00

    6/23/25 8:09:11 AM ET
    $SEPN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Septerna downgraded by Wells Fargo with a new price target

    Wells Fargo downgraded Septerna from Overweight to Equal Weight and set a new price target of $14.00

    2/18/25 8:55:10 AM ET
    $SEPN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Analyst initiated coverage on Septerna with a new price target

    Analyst initiated coverage of Septerna with a rating of Overweight and set a new price target of $38.00

    11/19/24 7:39:27 AM ET
    $SEPN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SEPN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Ezekowitz Alan bought $92,270 worth of shares (13,319 units at $6.93), increasing direct ownership by 13% to 117,420 units (SEC Form 4)

    4 - Septerna, Inc. (0001984086) (Issuer)

    3/10/25 4:18:19 PM ET
    $SEPN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Ezekowitz Alan bought $515,934 worth of shares (86,681 units at $5.95), increasing direct ownership by 498% to 104,101 units (SEC Form 4)

    4 - Septerna, Inc. (0001984086) (Issuer)

    3/6/25 9:02:51 PM ET
    $SEPN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CEO and President Finer Jeffrey bought $96,961 worth of shares (17,000 units at $5.70), increasing direct ownership by 2% to 771,907 units (SEC Form 4)

    4 - Septerna, Inc. (0001984086) (Issuer)

    2/27/25 6:53:01 PM ET
    $SEPN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SEPN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SVP, Biological Sciences Klein Uwe exercised 23,008 shares at a strike of $4.10 (SEC Form 4)

    4 - Septerna, Inc. (0001984086) (Issuer)

    8/19/25 5:02:20 PM ET
    $SEPN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Chief People Officer Shaikhly Samira

    4 - Septerna, Inc. (0001984086) (Issuer)

    8/11/25 7:11:23 PM ET
    $SEPN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by President and COO Bhatt Elizabeth

    4 - Septerna, Inc. (0001984086) (Issuer)

    8/11/25 7:09:59 PM ET
    $SEPN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SEPN
    SEC Filings

    View All

    Septerna Inc. filed SEC Form 8-K: Regulation FD Disclosure

    8-K - Septerna, Inc. (0001984086) (Filer)

    9/3/25 7:00:21 AM ET
    $SEPN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Septerna Inc. filed SEC Form 8-K: Regulation FD Disclosure

    8-K - Septerna, Inc. (0001984086) (Filer)

    8/21/25 8:33:01 AM ET
    $SEPN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Septerna Inc.

    10-Q - Septerna, Inc. (0001984086) (Filer)

    8/11/25 4:11:42 PM ET
    $SEPN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SEPN
    Leadership Updates

    Live Leadership Updates

    View All

    Septerna Expands Leadership with Appointment of Industry Veteran Gil Labrucherie as Chief Financial Officer

    SOUTH SAN FRANCISCO, Calif., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Septerna, Inc. (NASDAQ:SEPN), a clinical-stage biotech company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today announced the appointment of Gil Labrucherie, CFA, J.D., as Chief Financial Officer. Mr. Labrucherie is a seasoned biopharma executive with more than 25 years of senior leadership experience in finance and legal roles for public biopharmaceutical and technology companies. "We are excited to welcome Gil to the team," said Jeffrey Finer, M.D., Ph.D., Chief Executive Officer and Co-founder of Septerna. "His extensive expertise leading public company finance and capital strategy will be ins

    1/6/25 7:00:00 AM ET
    $SEPN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SEPN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D filed by Septerna Inc.

    SC 13D - Septerna, Inc. (0001984086) (Subject)

    11/4/24 4:39:38 PM ET
    $SEPN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Septerna Inc.

    SC 13G - Septerna, Inc. (0001984086) (Subject)

    11/4/24 4:15:38 PM ET
    $SEPN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Septerna Inc.

    SC 13G - Septerna, Inc. (0001984086) (Subject)

    11/1/24 4:27:45 PM ET
    $SEPN
    Biotechnology: Pharmaceutical Preparations
    Health Care